Jinny

[kinghano10000 @oZChlEQ9frKMQlt]

$nnox $ai
The Nanox Arc X brings next generation imaging to everyone, taking up less space, using less power, and providing more images,
Advanced Imaging has never been easier, one room & a standard outlet is all you need.

[kinghano10000 @oZChlEQ9frKMQlt]

$nnox $ai
Nanox Testimonial: Gregory Kicska, MD
Gregory Kicska, MD, PhD Cardiothoracic Imaging Associate Professor, University of Washington Veterans Health Administration, Seattle
https://t.co/LwPxRv10Yu

[kinghano10000 @oZChlEQ9frKMQlt]

$nnox $ai
Nanox Signs Distribution Agreement with Radiology Oncology Systems to Expand Nanox.ARC Adoption in the United States
https://t.co/gKtxqwZ25d

[kinghano10000 @oZChlEQ9frKMQlt]

$nnox $ai
Nanox Expands in Latin America with Exclusive Nanox. ARC Distribution.

Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market.

[kinghano10000 @oZChlEQ9frKMQlt]

$NNOX $AI #InvestorRelations #tomosynthesis #mbx $nvda
Enabling both 3D and 2D views from a single scan, without exposing the patient to any additional radiation
https://t.co/yhAohmqOvc

[kinghano10000 @oZChlEQ9frKMQlt]

$nnox $ai
This clinical video demonstrates a necrotic lung mass, highlighting thoracic findings visualized using the Nanox.ARC, a digital multi-source 3D tomosynthesis imaging system.
Nano-X Imaging - https://t.co/bB7wwltaWg

[Choice Choi @ChoiceChoi3]

$NNOX
$NANOX

[Choice Choi @ChoiceChoi3]

https://t.co/TDiUymRLsx
After completing field testing and clinical validation of product lineup (durability - performance, degradation defense mechanisms)

$NANOX appear to be beginning full-scale marketing and promotion.
$NNOX

#Arc-X
Tube (and Chip) OEM - All Industries
AI Solutions

Three years late to launch,
but three years early

It will dominate the global market.

[Choice Choi @ChoiceChoi3]

What I learned during the $NNOX feasibility study,

Despite the complete lack of recognition for 2D CXR as a equip for early "lung cancer screening",
approximately "33 million" cases are being performed annually, wasting valuable funds.

When $NANOX receives #TAP2D approval and becomes a standalone device,

the #Arc-X will creates a significant contribution,
while also reducing the cost of duplicate scans.

Even in terms of CapEx, the 3D tomosynthesis Arc-X, including end-to-end services, was found to be cheaper than the 2D CXR equipment + options.

[윤사사🛰 @ysasa44]

$NNOX

RSNA 2025 끝났네요.
현장에 있었던 사람들 말로는 부스 진짜 터졌다고 하고,
ARC X 실물 보고 다들 “이제 진짜 온다” 표정이었다고 합니다.
AI + 원격 판독 + OEM까지 한 번에 보여주니까
의사들, 파트너들, 애널리스트들 반응이 다 “이건 좀 다르다”였대요.

이제 진짜 시작이구나 싶네요.
2026년 기다려집니다.

https://t.co/Hs0ukxiw1I

[Choice Choi @ChoiceChoi3]

https://t.co/6x4OvA8yM9

$NANOX Arc-X
$NNOX

[kinghano10000 @oZChlEQ9frKMQlt]

$NNOX #InvestorRelations #tomosynthesis $ai #mbx #RSNA2025
Day 3 at RSNA! Nonstop demos. Growing media coverage. Momentum building fast.
There's still time to experience the Nanox. ARC X and our Al solutions in person.

[kinghano10000 @oZChlEQ9frKMQlt]

$NNOX #InvestorRelations $nvda $ai #mbx
Day 2 RSNA! The booth was buzzing all day. Full of curious clinicians, thoughtful conversations, and excitement about the Nanox. ARC X and our Al solutions.

[kinghano10000 @oZChlEQ9frKMQlt]

$NNOX #InvestorRelations $nvda #tomosynthesis $ai #mbx
Nanox.ARC X: Where Less Delivers More.
Bringing advanced 3D imaging to every point of care. https://t.co/NoPENeuOML

[Choice Choi @ChoiceChoi3]

The new $NANOX Arc-X glass tube has finally been revealed~!
$NNOX

[Choice Choi @ChoiceChoi3]

$NNOX $NANOX

Is it game changer?
Is it Right?

Journey to the AI Ready to AI intergrated.

[Choice Choi @ChoiceChoi3]

https://t.co/cBMhiOYgmz

$NANOX Imaging:
The Inflection Point That Value Investors Keep Missing

The #DanielJones`s Framework Problem.

Daniel Jones runs "Crude Value Insights," for $NNOX a cash-flow focused newsletter for oil and gas investors. His analytical rigor is well-suited to mature, capital-intensive businesses with predictable cash generation.

This is the wrong tool for evaluating medical device companies at commercial inflection points.

By his framework, Intuitive Surgical in 2003, DexCom in 2010, and Shockwave Medical in 2020 were all "uninvestable." Each delivered 10x+ returns to investors who recognized inflection points that backward-looking financials could not capture.

$NNOX is not oil and gas provider.

[Choice Choi @ChoiceChoi3]

$NNOX Arc's EU standalone approval serves as a leading indicator of the #FDA standalone transition, and $NANOX Arc-X is structured to follow that path.

Sources:
3q ER updated transscript
Press Release - official

[Jinny @Jerry081376]

@oZChlEQ9frKMQlt Wow! Happy news